ESMO 2026 | Evaluating SL-28 allogeneic leukocyte therapy in advanced solid tumors
George Tetz, PhD, Human Microbiology Institute, New York, NY, describes an interim analysis of SL-28, a novel off-the-shelf allogeneic leukocyte therapy enhanced ex vivo through TezR receptors, in a small cohort of heavily pretreated patients with stage IV solid tumors across two studies (NCT06872489; NCT07341737). Treatment was well tolerated, and responses, including complete responses, were seen across all tumor types. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So yesterday we have presented their personal human data for the novel cell therapy SL-28, which is the representative of a novel class of the cell therapy. It’s totally different from the existing therapeutic options like CAR-Ts and TILs. It’s based on their discovery of novel receptors on the surface of white blood cells, named Teasel, and an absolutely new way of how we can govern and activate and regulate the activity of human white blood cells...
So yesterday we have presented their personal human data for the novel cell therapy SL-28, which is the representative of a novel class of the cell therapy. It’s totally different from the existing therapeutic options like CAR-Ts and TILs. It’s based on their discovery of novel receptors on the surface of white blood cells, named Teasel, and an absolutely new way of how we can govern and activate and regulate the activity of human white blood cells. So we were showing how this novel approach works in patients with different types of biologically distinct advanced solid tumors. Yes, the data looks amazing so far. We have an objective response rate of more than 60 percent, with complete responses and partial responses, and the remaining patients were in stable disease, so the disease control rate is 100% across patients with different types of advanced solid tumors. The CAR-Ts and TILs do not work well in solid tumors, and SL28 does, and in a patient population that was used in the trial, they were heavily pretreated. These were patients who failed up to three lines of existing chemotherapy, immunotherapy. And in these harsh settings, in these patients, SL28 still worked and provided a huge benefit.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
